Nalfurafine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Nalfurafine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
Line 1: Line 1:
{{Drugbox
{{Drugbox
| IUPAC_name       = (''E'')-''N''-[17-(cyclopropylmethyl)-4,5α-epoxy-<br>3,14-dihydroxymorphinan-6β-yl]-3-(furan-3-yl)-<br>''N''-methylprop-2-enamide
| Verifiedfields = changed
| image             = Nalfurafine.svg
| Watchedfields = changed
| CAS_number        = 152658-17-8
| verifiedrevid = 447928192
| CAS_supplemental  =
| IUPAC_name = (2''E'')-''N''-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- ''N''-methylacrylamide
| ATC_prefix        =
| image = Nalfurafine.svg
| ATC_suffix        =
 
| ATC_supplemental  =
<!--Clinical data-->
| PubChem          = 6445230
| tradename =  
| DrugBank          =
| Drugs.com = {{drugs.com|international|nalfurafine}}
| C=28 | H=32 | N=2 | O=5
| licence_EU = <!-- EMEA requires brand name -->
| molecular_weight  = 476.564 g/mol
| licence_US = <!-- FDA may use generic name -->
| smiles            =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| synonyms          = TRK-820
| pregnancy_US = <!-- A / B            / C / D / X -->
| bioavailability  =
| pregnancy_category =  
| protein_bound    =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| metabolism        =
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| elimination_half-life =
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| excretion        =
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| licence_EU       = <!-- EMEA requires brand name -->  
| legal_status =  
| licence_US       = <!-- FDA may use generic name -->
| pregnancy_AU     = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US     = <!-- A / B            / C / D / X -->
| pregnancy_category=
| legal_AU         = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA         = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK         = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US         = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status     =  
| dependency_liability =  
| dependency_liability =  
| routes_of_administration = [[Intravenous therapy|intravenous]]
| routes_of_administration = [[Intravenous therapy|intravenous]]
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 152658-17-8
| ATC_prefix = V03
| ATC_suffix = AX02
| ATC_supplemental =
| PubChem = 6445230
| IUPHAR_ligand = 1651
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 267495
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XC41AVD567
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 4949003
<!--Chemical data-->
| C=28 | H=32 | N=2 | O=5
| molecular_weight = 476.564 g/mol
| synonyms = TRK-820
| smiles = CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7
| InChI            = 1/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3/b7-4+/t20-,22-,26+,27+,28-/m1/s1
| InChIKey          = XGZZHZMWIXFATA-UEZBDDGYBW
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3/b7-4+/t20-,22-,26+,27+,28-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey      = XGZZHZMWIXFATA-UEZBDDGYSA-N
}}
}}


'''Nalfurafine''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]]; also known as AC-820, TRK-820) is a [[kappa Opioid receptor|κ-opioid receptor]] [[agonist]] being developed as a treatment for [[Uremia|uremic]] [[pruritus]] in people undergoing [[hemodialysis]].
'''Nalfurafine''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]];<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/nalfurafine_hcl.pdf Statement on a Nonproprietary Name adopted by the USAN Council]</ref> also known as AC-820, TRK-820; trade name '''Remitch''') is a [[kappa Opioid receptor|κ-opioid receptor]] [[agonist]] marketed as a treatment for [[Uremia|uremic]] [[pruritus]] in people undergoing [[hemodialysis]].<ref>{{cite web|url=http://www.acologix.com/pipeline_ac-820.html|title=AC-820|publisher=Acologix|year=2009}}</ref>
 
{{as of|2010|1}}, it is also being investigated for the treatment of pruritus in patients with [[chronic liver disease]].<ref>{{ClinicalTrialsGov|NCT00638495|Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease}}</ref>
 
==References==
{{Reflist|2}}
 
 
{{Opioidergics}}


==External links==
[[Category:Morphinans]]
*http://www.ama-assn.org/ama1/pub/upload/mm/365/nalfurafine_hcl.pdf
[[Category:Phenols]]
*http://www.acologix.com/pipeline_ac-820.html
[[Category:Alcohols]]
[[Category:Amides]]
[[Category:Semisynthetic opioids]]
[[Category:Alkenes]]
[[Category:Furans]]
[[Category:Kappa agonists]]


{{pharma-stub}}


[[Category:Opioids]]
{{dermatologic-drug-stub}}
[[Category:Drugs]]
{{WikiDoc Sources}}

Revision as of 16:59, 13 April 2015

Nalfurafine
File:Nalfurafine.svg
Clinical data
SynonymsTRK-820
AHFS/Drugs.comInternational Drug Names
Routes of
administration		intravenous
ATC code
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC28H32N2O5
Molar mass476.564 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Nalfurafine (INN and USAN;[1] also known as AC-820, TRK-820; trade name Remitch) is a κ-opioid receptor agonist marketed as a treatment for uremic pruritus in people undergoing hemodialysis.[2]

As of January 2010, it is also being investigated for the treatment of pruritus in patients with chronic liver disease.[3]

References

  1. ↑ Statement on a Nonproprietary Name adopted by the USAN Council
  2. ↑ "AC-820". Acologix. 2009.
  3. ↑ Clinical trial number NCT00638495 for "Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease" at ClinicalTrials.gov



Template:Dermatologic-drug-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Nalfurafine&oldid=1086852"